XML 29 R20.htm IDEA: XBRL DOCUMENT v3.25.3

Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Accounting Policies [Abstract]

Percentage of Net Product Sales and Accounts Receivable Balance

The following table includes the percentage of net product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our product sales:

		Net Product Sales								Accounts Receivable
		Three Months Ended September 30, 2025				Nine Months Ended September 30, 2025				As of September 30, 2025
Customer A			38.8	%			42.2	%			40.6	%
Customer B			33.6	%			33.5	%			33.4	%
Customer C			25.8	%			22.8	%			25.5	%
Total			98.2	%			98.5	%			99.5	%

Schedule of Disaggregated Net Product Sales

The following table provides disaggregated net product sales (in thousands):

		Three Months Ended September 30,								Nine Months Ended September 30,
		2025				2024				2025				2024
CINVANTI net product sales		$	23,955			$	22,662			$	73,841			$	73,205
SUSTOL net product sales			1,911				2,763				7,175				10,623
ZYNRELEF net product sales			9,313				6,245				25,542				17,089
APONVIE net product sales			3,034				1,140				7,758				2,587
Total net product sales		$	38,213			$	32,810			$	114,316			$	103,504

Summary of Activity to Product Returns, Distributor Fees and Discounts, Rebates and Administrative Fees

The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):

		Product Returns				Distributor Fees				Discounts, Rebates and Administrative Fees				Total
Balance at December 31, 2024		$	3,791			$	5,883			$	27,745			$	37,419
Provision			1,544				25,949				170,019				197,512
Payments/credits			(842	)			(25,264	)			(167,462	)			(193,568	)
Balance at September 30, 2025		$	4,493			$	6,568			$	30,302			$	41,363

Common Stock Equivalents Excluded From Computation of Net Loss Per Share

Because we have incurred a net loss for the three and nine months ended September 30, 2025 and 2024, the following common stock equivalents were not included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):

		As of September 30,
		2025				2024
Stock options outstanding			28,888				26,156
Restricted stock units outstanding			4,014				1,547
Warrants outstanding			298				298
Shares of common stock underlying convertible notes outstanding			19,444				9,819
Series A Preferred Stock convertible to common shares			5,241				—

X

- Definition

Schedule of disaggregated net product sales.

+ References

No definition available.

+ Details

Name:	hrtx_ScheduleOfDisaggregatedNetProductSalesTableTextBlock
Namespace Prefix:	hrtx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.

+ References

No definition available.

+ Details

Name:	hrtx_ValuationAllowancesAndReservesTableTextBlock
Namespace Prefix:	hrtx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration